For those of us living in the Northern Hemisphere, the summer days are gone and the cooler days of fall have arrived. While it’s time to ditch the beachwear for chunky sweaters and a hot chocolate by the fire, things have been heating up in the longevity space.
Lifespan merges with SENS Research Foundation
Lifespan.io (Lifespan Extension Advocacy Foundation) and SENS Research Foundation are excited to announce the completion of their merger, forming a new 501(c)(3) non-profit: Lifespan Research Institute (LRI).
The new merged organization will develop, promote, and ensure widespread access to regenerative medicine solutions targeting the disabilities and diseases of aging, combining direct research efforts with robust education, affiliation, and outreach programs. The newly merged organization will focus on two core areas: Research and Outreach.
LRI’s research program will leverage our Research and Education Center in Mountain View, CA for targeted internal scientific projects and comprehensive education of the next generation of scientists and leaders.
The outreach program will encompass strong advocacy work necessary to propel the industry’s research and momentum forward through the Longevity Investor Network, news outlet, and other initiatives. With this new structure, the organization is positioned to drive greater impact by delivering solutions that directly tackle the effects of biological aging.
You can learn more about this exciting merging of two of the leading non-profit orgs in the longevity space by reading the full Lifespan Research Institute press release.
The Importance of Collaboration 2024 Longevity Frontiers Workshop
On July 28-29, the 2024 Longevity Frontiers Workshop was jointly hosted by the Longevity Biotech Fellowship and Foresight Institute.
The workshop brought together leading experts from research, investment, and entrepreneurship. The goal was to discuss and create projects designed to break the bottlenecks in five key focus areas:
- Acceleration: Tools to increase the rate of progress in biotech
- Replacement: Bypass aging complexity by swapping old for young tissue
- Bioengineering: Measuring, modeling and gene delivery to solve aging
- Biostasis: Saving lives with reversible stasis for organs and full humans
- Healthcare 3.0: Affordable health and lifespan extension for all of humanity
Lifespan.io Executive Director Stephanie Dainow was at the workshop and discussed the merger of Lifespan.org and SENS Research Foundation, signifying industry momentum. She highlights the importance of collaboration and challenges the audience to think differently.
Stephanie emphasized the need for effective communication and marketing in aging research, suggesting the need to understand public perceptions and tailor narratives accordingly.
- Lifespan.org and SENS Research Foundation have merged, indicating significant industry momentum.
- A state-of-the-art research facility exists near Mountain View, which Stephanie has been visiting and is now the chief business officer at.
- Lifespan and SENS Research Foundation are fostering collaboration and education in longevity research.
- The organizations are offering lab space and equipment for startups and educational opportunities for aspiring longevity scientists.
- Stephanie is actively working to connect investors with longevity research and startups.
- Lifespan.org operates a news outlet with a strict code of ethics, refusing to write about companies for payment.
- The organizations aim to be a one-stop shop for longevity research, offering visibility, funding, and support services.
- Startups supported by these services have had a success rate of over 65% in securing six-figure offers.
- Marketing longevity research requires reframing complex science into understandable terms for the public.
- Stephanie emphasizes the importance of storytelling and understanding the audience’s perspective when communicating about longevity.
The PEARL rapamycin clinical trial webinar
On August 27th at 1 PM EST, there was a special webinar for backers of the PEARL research fundraiser hosted by AgelessRX with guests from Lifespan.io.
PEARL was an AgelessRX project hosted back in 2021 on our website and is short for Participatory Evaluation of Aging with Rapamycin for Longevity. The campaign raised $182,838, hit 2 stretch goals to expand the scope of the study, and ended at 243% funding.
The participants of the webinar were:
- Girish Harinath
- Dr. Zalzala
- Matt Kaeberlein
- Keith Comito
- Oliver Medvedik
The webinar allowed participants to see the latest PEARL research data, ask questions, and join in with the discussion about the future of the project. For those of you who could not make it, we have made the recording available for you to enjoy.
We will continue to deliver the best longevity news for you
On top of the exciting merger, rest assured that the news outlet will continue to bring you the latest longevity news and educational topics right here at Lifespan.io, so there is no need to change your bookmarks!
Transparency and professional journalism have long been a cornerstone of what we do here at the Lifespan.io news outlet, so much so that we created an Ethics Code of Longevity Journalism.
This code was created to help us to maintain a trusted source of information for people who are interested in longevity and aging research. Ours is a complex field that is rapidly evolving, and there is a literal information storm to navigate as well as perils such as snake oil salesmen, fraud, and fake news.
“We have long been a trusted source of information about the field and our commitment to quality and accessible journalism will continue. When I first created the news outlet, it was with the goal of providing the community and public with a source of information they could trust, free from commercial and government influence. There is a significant amount of dishonest and misleading information about longevity, usually with the aim to sell questionable supplements or ‘therapies’, out there, and it was my goal and that of Lifespan.io to challenge this. I look forward to continuing this tradition under the banner of the Lifespan Research Institute” – Steve Hill, Editor in Chief
Our commitment to quality and accessible journalism will continue, and you can rely on us for the best longevity news coverage.
Expanding our coverage following the audience survey
Earlier this year, we conducted a large-scale audience survey: we listened to what you had to say and the kinds of content you wanted to see, and we are acting on that now. Many thanks to those of you who took the time to share your thoughts on the future of Lifespan.io’s news outlet.
You can expect more special feature articles, interviews, and reports on the rejuvenation biotech side of the field. Our goal is to bring you more in-depth coverage and commentary from the leading researchers in the field, helping you to stay informed.
We are expanding our scope to bring you more rejuvenation biotech business news. Our readers have told us that it’s important to them to understand the investment and funding landscape in our field and to get a feel for how things are going. With that in mind, we are working on some special reports that will focus on the impact of the decentralized science (DeSci) funding model on research funding, the level of investment in rejuvenation biotech over recent years, and more.
Many of you are probably familiar with the Longevity Investor Network (LIN), which we created a few years ago. The LIN brings investors and promising rejuvenation biotech startups together to drive progress in the field at the clinical stage. We plan to collaborate with the LIN to bring expert commentary on the business side of the field. If you are an investor and are interested in applying to join the LIN, please get in touch using the application form on the Longevity Investor Network page.
The merge also means we can bring you even more news! As the LRI, we have a state-of-the-art research facility in Mountain View, California. Therefore, you can expect us to bring you all the exciting news about our research on aging programs directly from our lab in the near future.
Stay up to date, join the newsletter!
If you want to keep up with the latest research news, then feel free to join our newsletter. We will see you in the next editorial closer to the holidays with more updates and news on what our new organization has been doing to defeat age-related diseases.
